In contrast, in nephropathy, IL-18 is not an important AKI biomarker, and the exact mechanisms by which each biomarker changes in different clinical situations have yet to be well revealed, and it has been suggested that different clinical situations should identify specific AKI biomarkers to enhance the initial detection and mediation of subclinical AKI. This evidence concerns the gene IL18 and acute kidney injury.